title: Matrine inhibits the invasive properties of human osteosarcoma cells by downregulating the ERK-NF-κB pathway.
abstract: Matrine has been used in anti-inflammatory and anticancer therapies for a long time. However, the antimetastatic effect and molecular mechanism(s) of matrine on osteosarcoma are still unclear. Therefore, the aim of this study was to assess the effects of matrine and related mechanism(s) on osteosarcoma cells. In the study, we found that matrine inhibited the proliferation of osteosarcoma cells in vivo and in vitro and inhibited tumor cell metastasis in vitro at cytotoxic doses. Matrine also decreased the expression of the matrix metalloproteinases-2 and 9, decreased p50 and p65 nuclear translocation, and decreased the phosphorylated level of I-κ-B (IκB)-β. In addition, matrine reduced the phosphorylated levels of extracellular signal-regulated kinase 1/2 proteins, which regulate the invasion of poorly differentiated cancer cells. Finally, when U2OS cells were grown as xenografts in nude mice, intragastric administration of matrine induced a significant dose-dependent decrease in tumor growth. These results show the anticancer properties of matrine, which include the inhibition of invasion and proliferation of human osteosarcoma cells.
authors.affiliation: aHospital Department of Foot and Ankle Surgery, Hong Hui Hospital, Xi'an Jiaotong University College of Medicine bAnesthesia Department, The Second Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, People's Republic of China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Li
authors.forename: Zhen-Ni
authors.initials: ZN
authors.lastname: Zhang
authors.forename: Hong-Mou
authors.initials: HM
authors.lastname: Zhao
authors.forename: Zhi-Chao
authors.initials: ZC
authors.lastname: Tong
authors.forename: Jie
authors.initials: J
authors.lastname: Yang
authors.forename: Hu
authors.initials: H
authors.lastname: Wang
authors.forename: Xiao-Jun
authors.initials: XJ
authors.lastname: Liang
mesh_terms: D000470:Alkaloids / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000473:pathology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D015536:Down-Regulation; D064593:Heterografts; D006801:Humans; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism*; D009361:Neoplasm Invasiveness / Q000473:pathology; D012516:Osteosarcoma / Q000188:drug therapy / Q000473:pathology*; D010766:Phosphorylation; D011807:Quinolizines / Q000494:pharmacology* / Q000627:therapeutic use; D015398:Signal Transduction; D000093842:Matrines
chemical_list: D000470:Alkaloids; D000970:Antineoplastic Agents; D016328:NF-kappa B; D011807:Quinolizines; C535150:MAPK1 protein, human; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; D000093842:Matrines